LIPUM

Lipum is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases... Lipum AB (publ) is a clinical phase biopharmaceutical company specializing in the discovery and development of new treatments for chronic inflammatory diseases. The drug candidate SOL-116 is a humanized monoclonal antibody being evaluated to provide safer and more effective treatment by blocking a previously overlooked target molecule in the immune system, the Bile Salt-Stimulated Lipase (BSSL). SOL-116 is in clinical phase with compelling preclinical data for rheumatoid arthritis (RA). Lipum is also evaluating other inflammatory diseases with significant unmet medical needs... Lipum's office and a laboratory reside within Uminova Science Park in Umeå. Development work is conducted with support from contracted consultants with specialist expertise in various aspects of drug development, as well as support from scientific advisors. Contract Research Organizations (CROs) are..

Also known as: Lipum AB, Lipum AB (publ)

Registration numbers: 556813-5999 (W)

VAT numbers: SE556813599901

Primary location: Umeå Sweden